MCID: HYP083
MIFTS: 59

Hypopituitarism

Categories: Rare diseases, Endocrine diseases, Genetic diseases

Aliases & Classifications for Hypopituitarism

MalaCards integrated aliases for Hypopituitarism:

Name: Hypopituitarism 12 72 49 36 28 51 41 14 69
Pituitary Insufficiency 12 49
Pituitary Hormone Deficiency 12
Pituitary Hypofunction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9406
ICD10 32 E23.0 E23
MeSH 41 D007018
NCIt 46 C62591
KEGG 36 H01700
UMLS 69 C0020635

Summaries for Hypopituitarism

NIH Rare Diseases : 49 Hypopituitarism occurs when the body has low levels of certain hormones made by the pituitary gland.  The pituitary gland normally makes several hormones (including growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, prolactin, follicle stimulating hormone and luteinizing hormone, vasopressin, and oxytocin).  These hormones are important for directing body growth and development, and for regulating blood pressure and metabolism.  Symptoms of this condition vary and depend on which hormones are affected.  Treatment depends on the cause of this condition; once the cause is corrected, medication (hormone replacement therapy) must be taken to provide the body with the normal amount of hormones. Last updated: 7/20/2012

MalaCards based summary : Hypopituitarism, also known as pituitary insufficiency, is related to combined pituitary hormone deficiencies, genetic forms and lymphocytic hypophysitis. An important gene associated with Hypopituitarism is PROP1 (PROP Paired-Like Homeobox 1), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and p70S6K Signaling. The drugs Testosterone and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and testes, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 A pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland.

Wikipedia : 72 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Related Diseases for Hypopituitarism

Diseases in the Hypopituitarism family:

Familial Hypopituitarism

Diseases related to Hypopituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 364)
# Related Disease Score Top Affiliating Genes
1 combined pituitary hormone deficiencies, genetic forms 32.3 GLI2 HESX1 LHX4 POU1F1 PROP1
2 lymphocytic hypophysitis 32.1 GH1 POMC
3 sheehan syndrome 32.0 CRH IGF1 INS POMC PRL
4 septooptic dysplasia 31.3 HESX1 LHX3 LHX4 POU1F1 PROP1 SOX3
5 isolated growth hormone deficiency 30.5 GH1 GHRH HESX1 IGF1 LHX3 LHX4
6 isolated growth hormone deficiency, type iii 30.3 HESX1 SOX3
7 pituitary hormone deficiency, combined, 2 30.2 GH1 HESX1 IGF1 LHX3 LHX4 POMC
8 adenoma 29.8 GH1 IGF1 POMC PRL
9 gigantism 29.8 GH1 GHRH PRL
10 galactorrhea 29.8 IGF1 PRL
11 diabetes insipidus 29.7 CRH INS POMC PRL
12 functioning pituitary adenoma 29.6 GH1 POMC PRL
13 turner syndrome 29.6 GH1 IGF1 IGFBP3
14 isolated growth hormone deficiency, type ii 29.6 GH1 GHRH HESX1 IGF1 POU1F1
15 hypothalamic disease 29.6 CRH GH1 GHRH GNRH1 POMC PRL
16 hypoadrenalism 29.5 CRH GH1 POMC
17 isolated growth hormone deficiency, type ib 29.5 GH1 GHRH IGF1 IGFBP3
18 diabetes insipidus, neurohypophyseal 29.4 GNRH1 POMC PRL
19 kallmann syndrome 29.3 GNRH1 HESX1 LHX3 PROP1
20 hyperthyroidism 29.3 GH1 INS PRL
21 hyperinsulinism 29.3 IGF1 IGFBP3 INS
22 adenohypophysitis 29.3 GH1 POMC PRL
23 secondary adrenal insufficiency 29.3 IGF1 IGFBP3 INS
24 pituitary adenoma, prolactin-secreting 29.2 GH1 IGF1 POMC PRL
25 acth deficiency, isolated 29.2 CRH POMC
26 combined pituitary hormone deficiency 29.1 HESX1 LHX3 LHX4 POU1F1 PROP1
27 hypogonadotropism 29.1 GNRH1 PRL
28 growth hormone deficiency 29.0 GH1 GHRH HESX1 IGF1 IGFBP3 PROP1
29 pituitary apoplexy 29.0 GNRH1 INS POMC PRL
30 pituitary hypoplasia 28.9 HESX1 LHX3 LHX4 POU1F1 PRL SOX3
31 chiasmal syndrome 28.9 GNRH1 POMC PRL
32 pituitary tumors 28.7 GH1 IGF1 POMC POU1F1 PRL PROP1
33 pituitary stalk interruption syndrome 28.6 GH1 HESX1 LHX4 POU1F1 PRL SOX3
34 craniopharyngioma 28.5 GNRH1 IGF1 INS POU1F1 PRL PROP1
35 empty sella syndrome 28.5 GH1 GNRH1 INS POMC PRL
36 pituitary adenoma 28.5 CRH GH1 GHRH IGF1 POMC POU1F1
37 amenorrhea 28.1 CRH GNRH1 POMC PRL
38 acromegaly 28.1 GH1 GHRH IGF1 IGFBP3 INS POMC
39 insulin-like growth factor i 28.0 GH1 GHRH IGF1 IGFBP3 INS PRL
40 bulimia nervosa 2 28.0 CRH GH1 GHRH IGF1 POMC PRL
41 body mass index quantitative trait locus 11 27.9 CRH GH1 GHRH IGF1 IGFBP3 INS
42 hyperprolactinemia 27.9 GH1 GHRH GNRH1 IGF1 POMC PRL
43 chromophobe adenoma 27.7 GH1 GHRH GNRH1 INS POMC PRL
44 hyperpituitarism 27.5 GH1 GHRH IGF1 IGFBP3 INS POMC
45 pituitary gland disease 25.9 CRH GH1 GHRH GNRH1 HESX1 IGF1
46 anterior pituitary insufficiency, familial 12.0
47 choroideremia hypopituitarism 12.0
48 familial hypopituitarism 12.0
49 arthrogryposis, distal, with hypopituitarism, mental retardation, and facial anomalies 11.8
50 hypopituitarism, congenital, with central diabetes insipidus 11.8

Graphical network of the top 20 diseases related to Hypopituitarism:



Diseases related to Hypopituitarism

Symptoms & Phenotypes for Hypopituitarism

MGI Mouse Phenotypes related to Hypopituitarism:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.35 GLI2 GNRH1 HESX1 IGF1 IGFBP3 INS
2 homeostasis/metabolism MP:0005376 10.28 GLI2 GNRH1 IGF1 IGFBP3 INS LHX3
3 growth/size/body region MP:0005378 10.27 CRH GHRH GLI2 GNRH1 HESX1 IGF1
4 nervous system MP:0003631 10.17 CRH GHRH GLI2 GNRH1 HESX1 IGF1
5 integument MP:0010771 10.01 CRH GLI2 GNRH1 IGF1 IGFBP3 INS
6 liver/biliary system MP:0005370 9.91 CRH GHRH GNRH1 IGFBP3 INS POMC
7 reproductive system MP:0005389 9.85 IGF1 INS LHX3 POU1F1 PRL PROP1
8 renal/urinary system MP:0005367 9.73 CRH GNRH1 IGF1 IGFBP3 INS POMC
9 respiratory system MP:0005388 9.5 PROP1 CRH GLI2 HESX1 IGF1 IGFBP3
10 skeleton MP:0005390 9.23 CRH GLI2 GNRH1 IGF1 IGFBP3 INS

Drugs & Therapeutics for Hypopituitarism

Drugs for Hypopituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone Approved, Investigational Phase 4,Phase 2 58-22-0 6013
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-23-7 657311 5754
3
Epinephrine Approved, Vet_approved Phase 4,Phase 3 51-43-4 5816
4
Cosyntropin Approved Phase 4 16960-16-0 16129617
5
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
6 Racepinephrine Approved Phase 4,Phase 3 329-65-7
7
Butyric Acid Experimental, Investigational Phase 4,Early Phase 1 107-92-6 264
8 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Cortisol succinate Phase 4,Phase 3,Early Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Early Phase 1
15 Hydrocortisone acetate Phase 4,Phase 3,Early Phase 1
16 Hydrocortisone-17-butyrate Phase 4,Early Phase 1
17 Anti-Inflammatory Agents Phase 4,Early Phase 1
18 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Testosterone undecanoate Phase 4,Phase 2
20
Testosterone enanthate Phase 4,Phase 2 315-37-7 9416
21 Respiratory System Agents Phase 4
22 Adrenergic Agents Phase 4,Phase 3,Phase 2
23 Adrenergic Agonists Phase 4,Phase 3
24 Adrenergic alpha-Agonists Phase 4,Phase 3
25 Testosterone 17 beta-cypionate Phase 4,Phase 2
26 Anabolic Agents Phase 4,Phase 2
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
28 Growth Hormone-Releasing Hormone Phase 4,Phase 3,Phase 2,Phase 1
29 Androgens Phase 4,Phase 2
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
31 Epinephryl borate Phase 4,Phase 3
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
33 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
34 Autonomic Agents Phase 4,Phase 3
35 Mydriatics Phase 4
36 Adrenergic beta-Agonists Phase 4
37 Vasoconstrictor Agents Phase 4
38 Anti-Asthmatic Agents Phase 4
39 Bronchodilator Agents Phase 4
40
Zinc Approved, Investigational Phase 3,Early Phase 1 7440-66-6 32051 23994
41
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
42
Clonidine Approved Phase 3 4205-90-7 2803
43
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
44 tannic acid Approved, Nutraceutical Phase 3
45 Hypoglycemic Agents Phase 3,Early Phase 1
46 Analgesics Phase 3,Phase 2
47 Adrenergic alpha-2 Receptor Agonists Phase 3
48 Steroid Synthesis Inhibitors Phase 2, Phase 3
49 Sympatholytics Phase 3
50 Estrogen Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 238)

# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
2 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
3 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
4 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
5 Testosterone Gel Applied to Women With Pituitary Gland Problems Completed NCT00144391 Phase 4 Transdermal Testosterone gel
6 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
7 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4 Thyroxin, Triiodothyronine
8 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
9 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
10 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
11 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
12 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
13 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
14 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
15 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
16 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
17 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
18 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
19 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
20 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Human Growth Hormone;Placebo
21 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
22 Easypod United States User Trial Completed NCT00689260 Phase 4
23 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
24 A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency Completed NCT00455884 Phase 4
25 Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD) Completed NCT00097526 Phase 4
26 Predictive Markers in GHD and TS Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen
27 IGF1 Generation Test Completed NCT00145457 Phase 4
28 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
29 National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients Completed NCT00097513 Phase 4
30 Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children Recruiting NCT03290235 Phase 4 PEG-somatropin
31 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT03249480 Phase 4
32 Body Composition and Adipose Tissue in HIV Recruiting NCT03226821 Phase 4 Tesamorelin
33 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT02976675 Phase 4
34 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Recruiting NCT02908958 Phase 4
35 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Recruiting NCT03015909 Phase 4 Somatropin
36 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I) Recruiting NCT02380235 Phase 4
37 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
38 Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency Terminated NCT01698944 Phase 4 somatropin
39 A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury Terminated NCT00638053 Phase 4
40 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury Terminated NCT00555009 Phase 4 Genotropin;Placebo
41 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury. Withdrawn NCT00432263 Phase 4 Genotropin (PN-180,307) Somatropin
42 Treatment of Children With Insufficient Secretion of Growth Hormone Unknown status NCT00271518 Phase 3 growth hormone (somatropin)
43 Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency Completed NCT01007071 Phase 3 Human Growth Hormone (1-134);Placebo
44 Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys Completed NCT00133354 Phase 2, Phase 3 Arimidex (Anastrozole);Placebo;Growth Hormone
45 Treatment of Adrenal Insufficiency in Children Completed NCT02720952 Phase 3 Infacort®
46 Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency Completed NCT03223025 Phase 3 CinnaTropin®;Nordilet®
47 Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency Completed NCT02693522 Phase 3 somatropin;Eutropin
48 Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency Completed NCT02558829 Phase 3 Macimorelin;Insulin
49 A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency Completed NCT02382939 Phase 3 somapacitan;somatropin
50 A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency Completed NCT02173821 Phase 3

Search NIH Clinical Center for Hypopituitarism

Cochrane evidence based reviews: hypopituitarism

Genetic Tests for Hypopituitarism

Genetic tests related to Hypopituitarism:

# Genetic test Affiliating Genes
1 Hypopituitarism 28

Anatomical Context for Hypopituitarism

MalaCards organs/tissues related to Hypopituitarism:

38
Pituitary, Brain, Testes, Thyroid, Bone, Heart, Endothelial

Publications for Hypopituitarism

Articles related to Hypopituitarism:

(show top 50) (show all 740)
# Title Authors Year
1
Pathogenic copy number variants in patients with congenital hypopituitarism associated with complex phenotypes. ( 29265571 )
2018
2
Cerebrofacial arteriovenous metameric syndrome with hypopituitarism: a rare association. ( 29330274 )
2018
3
Congenital Hyperinsulinism and Hypopituitarism Attributable to a Novel Mutation in FOXA2. ( 29329447 )
2018
4
Intracranial germinoma causing cerebral haemiatrophy and hypopituitarism. ( 29378909 )
2018
5
Congenital Hypopituitarism. ( 29406008 )
2018
6
Hypopituitarism 3 and 12 months after traumatic brain injury and subarachnoid haemorrhage. ( 29283287 )
2018
7
Neonatal hypoglycemia, early-onset diabetes and hypopituitarism due to the mutation in EIF2S3 gene causing MEHMO syndrome. ( 29303605 )
2018
8
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. ( 29313195 )
2018
9
A heterozygous microdeletion of 20p12.2-3 encompassing PROKR2 and BMP2 in a patient with congenital hypopituitarism and growth hormone deficiency. ( 28586151 )
2017
10
Russell's viper envenomation: acute hypopituitarism or acute primary adrenal insufficiency. ( 28339821 )
2017
11
Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability. ( 28597171 )
2017
12
Getting to the heart of hypopituitarism. ( 28365624 )
2017
13
Acute hypopituitarism associated with periorbital swelling and cardiac dysfunction in a patient with pituitary tumor apoplexy: a case report. ( 28835258 )
2017
14
Hypopituitarism after gamma knife radiosurgery for pituitary adenoma. ( 28537768 )
2017
15
Sex steroids and the GH axis: Implications for the management of hypopituitarism. ( 28477733 )
2017
16
Response: Russell's viper envenomation: acute hypopituitarism or acute primary adrenal insufficiency. ( 28339808 )
2017
17
Brain Malformations Do Not Predict Hypopituitarism in Young Children with Optic Nerve Hypoplasia. ( 28848142 )
2017
18
Impact of etiology, age and gender on onset and severity of hyponatremia in patients with hypopituitarism: retrospective analysis in a specialised endocrine unit. ( 28913704 )
2017
19
Hypopituitarism and hypothyroidism following atrioventricular block during nivolumab treatment. ( 28295551 )
2017
20
Multi-genic pattern found in rare type of hypopituitarism: a whole-exome sequencing study of Han Chinese with pituitary stalk interruption syndrome. ( 28707430 )
2017
21
Hospitalisation in Children with Adrenal Insufficiency and Hypopituitarism: Is There a Differential Burden between Boys and Girls and between Age Groups? ( 28898882 )
2017
22
Hyponatraemia and hypopituitarism: an easily missed entity. ( 28954609 )
2017
23
Novel FOXA2 mutation causes Hyperinsulinism, Hypopituitarism with Craniofacial and Endoderm-derived organ abnormalities. ( 28973288 )
2017
24
Etiology of Hypopituitarism in Adult Patients: The Experience of a Single Center Database in the Serbian Population. ( 28702053 )
2017
25
Hypopituitarism (Panhypopituitarism) ( 29262053 )
2017
26
A Case of Congenital Hypopituitarism Associated With a 1p31 Microdeletion: A Possible Role for<i>LEPR</i>and<i>JAK1</i>. ( 29264484 )
2017
27
Getting to the heart of hypopituitarism. ( 28765432 )
2017
28
Diabetes insipidus and hypopituitarism in HIV: an unexpected cause. ( 28620498 )
2017
29
Analysis of Factors Related to Hypopituitarism in Patients with Nonsellar Intracranial Tumor. ( 28552700 )
2017
30
Advances in understanding hypopituitarism. ( 28299199 )
2017
31
IgG4-related Hypophysitis with Subtle Hypopituitarism in an Elderly Diabetic Patient: Is Treatment or Observation Preferable? ( 28924128 )
2017
32
Unusual association of turner syndrome and hypopituitarism in a Tunisian family. ( 27140594 )
2016
33
Reversible Hypopituitarism Associated with Intravascular Large B-Cell Lymphoma: Case Report of Successful Immunochemotherapy. ( 26936510 )
2016
34
Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury. ( 27878771 )
2016
35
Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism. ( 26928716 )
2016
36
Evaluation and Initial Management of Hypopituitarism. ( 27587639 )
2016
37
CARDIAC STRUCTURAL AND FUNCTIONAL ABNORMALITIES IN FEMALES WITH UNTREATED HYPOPITUITARISM DUE TO SHEEHAN SYNDROME: RESPONSE TO HORMONE REPLACEMENT THERAPY. ( 27359291 )
2016
38
VARIATIONS IN CLINICAL AND IMAGING FINDINGS BY TIME OF DIAGNOSIS IN FEMALES WITH HYPOPITUITARISM ATTRIBUTED TO LYMPHOCYTIC HYPOPHYSITIS. ( 26595515 )
2016
39
Hypopituitarism Presenting as Adrenal Insufficiency and Hypothyroidism in a Patient with Wilson's Disease: a Case Report. ( 27478349 )
2016
40
Circulating MicroRNAs as Potential Biomarkers for Traumatic Brain Injury-Induced Hypopituitarism. ( 27027233 )
2016
41
Cholesteatoma in the Sellar Region Presenting as Hypopituitarism and Diabetes Insipidus. ( 26962793 )
2016
42
Concurrent hypopituitarism and leukemic retinopathy in a child with B-precursor acute lymphoblastic leukemia and isolated central nervous system relapse. ( 27536191 )
2016
43
Cancerous leptomeningitis and familial congenital hypopituitarism. ( 26886902 )
2016
44
Mortality in adults with hypopituitarism: a systematic review and meta-analysis. ( 27817141 )
2016
45
The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke. ( 27815769 )
2016
46
Human Pluripotent-Derived Lineages for Repairing Hypopituitarism ( 28590707 )
2016
47
Hypopituitarism following rifle cleaning accident. ( 27934815 )
2016
48
A patient with pseudohypoaldosteronism type II complicated by congenital hypopituitarism carrying a KLHL3 mutation. ( 27780982 )
2016
49
Hypopituitarism in the elderly: a narrative review on clinical management of hypothalamic-pituitary-gonadal, hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes dysfunction. ( 27209187 )
2016
50
Hypopituitarism: An uncommon cause of developmental delay. ( 27452620 )
2016

Variations for Hypopituitarism

Expression for Hypopituitarism

Search GEO for disease gene expression data for Hypopituitarism.

Pathways for Hypopituitarism

Pathways related to Hypopituitarism according to KEGG:

36
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

GO Terms for Hypopituitarism

Cellular components related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 CRH GH1 GHRH GNRH1 IGF1 IGFBP3
2 extracellular region GO:0005576 9.91 CRH GH1 GHRH GNRH1 IGF1 IGFBP3
3 insulin-like growth factor ternary complex GO:0042567 9.16 IGF1 IGFBP3
4 insulin-like growth factor binding protein complex GO:0016942 8.96 IGF1 IGFBP3
5 endosome lumen GO:0031904 8.8 GH1 INS PRL

Biological processes related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.91 GHRH GNRH1 INS POMC
2 negative regulation of apoptotic process GO:0043066 9.85 GLI2 GNRH1 IGF1 LHX3 LHX4 PROP1
3 cellular protein metabolic process GO:0044267 9.84 IGF1 IGFBP3 INS PRL
4 animal organ morphogenesis GO:0009887 9.8 LHX3 LHX4 PROP1
5 positive regulation of cell proliferation GO:0008284 9.8 CRH GHRH GLI2 IGF1 INS POU1F1
6 lung development GO:0030324 9.76 CRH GLI2 LHX3
7 positive regulation of MAPK cascade GO:0043410 9.75 IGF1 IGFBP3 INS
8 female pregnancy GO:0007565 9.74 CRH GNRH1 PRL
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 GH1 IGF1 INS
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 GH1 IGF1 INS
11 regulation of receptor activity GO:0010469 9.7 GH1 GHRH GNRH1 IGF1 INS POMC
12 positive regulation of DNA replication GO:0045740 9.65 GLI2 IGF1 INS
13 motor neuron axon guidance GO:0008045 9.64 LHX3 LHX4
14 positive regulation of glycolytic process GO:0045821 9.63 IGF1 INS
15 positive regulation of JAK-STAT cascade GO:0046427 9.63 GH1 PRL
16 dorsal/ventral pattern formation GO:0009953 9.63 GLI2 LHX3 PROP1
17 positive regulation of glycogen biosynthetic process GO:0045725 9.62 IGF1 INS
18 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 GH1 PRL
19 positive regulation of multicellular organism growth GO:0040018 9.61 GH1 GHRH POU1F1
20 hypothalamus development GO:0021854 9.59 CRH SOX3
21 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.52 IGFBP3 POU1F1
22 somatotropin secreting cell differentiation GO:0060126 9.51 POU1F1 PROP1
23 adenohypophysis development GO:0021984 9.43 GHRH POU1F1 PROP1
24 medial motor column neuron differentiation GO:0021526 9.4 LHX3 LHX4
25 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
26 pituitary gland development GO:0021983 9.02 GLI2 HESX1 LHX3 POU1F1 SOX3
27 regulation of transcription, DNA-templated GO:0006355 10.25 GLI2 HESX1 INS LHX3 LHX4 POU1F1
28 negative regulation of transcription by RNA polymerase II GO:0000122 10.04 GLI2 HESX1 POU1F1 PROP1 SOX3
29 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 GLI2 IGF1 LHX3 LHX4 POMC POU1F1
30 transcription by RNA polymerase II GO:0006366 10 GLI2 LHX3 LHX4 POU1F1 PROP1

Molecular functions related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.67 GLI2 HESX1 POU1F1 PROP1
2 sequence-specific DNA binding GO:0043565 9.63 GLI2 HESX1 LHX3 LHX4 POU1F1 PROP1
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.62 GLI2 HESX1 LHX3 POU1F1
4 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS
5 hormone activity GO:0005179 9.17 CRH GH1 GNRH1 IGF1 INS POMC
6 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hypopituitarism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....